[go: up one dir, main page]

RU2018135652A - IMMUNOCOMPETENT CELL AND EXPRESSING VECTOR, EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION - Google Patents

IMMUNOCOMPETENT CELL AND EXPRESSING VECTOR, EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION Download PDF

Info

Publication number
RU2018135652A
RU2018135652A RU2018135652A RU2018135652A RU2018135652A RU 2018135652 A RU2018135652 A RU 2018135652A RU 2018135652 A RU2018135652 A RU 2018135652A RU 2018135652 A RU2018135652 A RU 2018135652A RU 2018135652 A RU2018135652 A RU 2018135652A
Authority
RU
Russia
Prior art keywords
nucleic acid
acid encoding
expression vector
cancer antigen
directed
Prior art date
Application number
RU2018135652A
Other languages
Russian (ru)
Other versions
RU2770812C2 (en
RU2018135652A3 (en
Inventor
Кодзи ТАМАДА
Юкими САКОДА
Кэиси АДАТИ
Original Assignee
Ямагути Университи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ямагути Университи filed Critical Ямагути Университи
Publication of RU2018135652A publication Critical patent/RU2018135652A/en
Publication of RU2018135652A3 publication Critical patent/RU2018135652A3/ru
Application granted granted Critical
Publication of RU2770812C2 publication Critical patent/RU2770812C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (28)

1. Иммунокомпетентная клетка, экспрессирующая молекулу клеточной поверхности, направлено распознающую раковый антиген, интерлейкин 7 (IL-7) и CCL19.1. An immunocompetent cell expressing a cell surface molecule is directed to recognize cancer antigen, interleukin 7 (IL-7) and CCL19. 2. Иммунокомпетентная клетка по п. 1, в которой молекула клеточной поверхности, направлено распознающая раковый антиген, представляет собой Т-клеточный рецептор, направлено распознающий раковый антиген.2. The immunocompetent cell according to claim 1, wherein the cell surface molecule directed to recognize the cancer antigen is a T-cell receptor directed to recognize the cancer antigen. 3. Иммунокомпетентная клетка по п. 1 или 2, в которой иммунокомпетентная клетка представляет собой Т-клетку.3. An immunocompetent cell according to claim 1 or 2, wherein the immunocompetent cell is a T cell. 4. Иммунокомпетентная клетка по пп. 1-3, в которых раковым антигеном является WT1, MART-1, NY-ESO-1, MAGE-A1, MAGE-A3, MAGE-A4, Glypican-3, KIF20A, Сурвивин, AFP-1, gp100, MUC1, РАР-10, РАР-5, TRP2-1, SART-1, VEGFR1, VEGFR2, NEIL3, MPHOSPH1, DEPDC1, FOXM1, CDH3, TTK, ТОММ34, URLC10, KOC1, UBE2T, TOPK, ЕСТ2, MESOTHELIN, NKG2D, P1A, GD2 или GM2.4. Immunocompetent cell according to paragraphs. 1-3, in which the cancer antigen is WT1, MART-1, NY-ESO-1, MAGE-A1, MAGE-A3, MAGE-A4, Glypican-3, KIF20A, Survivin, AFP-1, gp100, MUC1, PAP -10, PAP-5, TRP2-1, SART-1, VEGFR1, VEGFR2, NEIL3, MPHOSPH1, DEPDC1, FOXM1, CDH3, TTK, TOMM34, URLC10, KOC1, UBE2T, TOPK, EC2, MESOTHELIN, NKG2, or GM2. 5. Экспрессирующий вектор для генерирования иммунокомпетентной клетки в соответствии с любым из пп. 1-4, представляет собой любой из следующих (а)-(е):5. An expression vector for generating an immunocompetent cell in accordance with any one of paragraphs. 1-4, represents any of the following (a) - (e): а) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую молекулу клеточной поверхности, направлено распознающую раковый антиген, нуклеиновую кислоту, кодирующую IL-7, и нуклеиновую кислоту, кодирующую CCL19;a) an expression vector containing a nucleic acid encoding a cell surface molecule is directed to recognize a cancer antigen, a nucleic acid encoding IL-7, and a nucleic acid encoding CCL19; (b) следующие два экспрессирующих вектора (b-1) и (b-2):(b) the following two expression vectors (b-1) and (b-2): (b-1) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую молекулу клеточной поверхности, направлено распознающую раковый антиген; а также(b-1) an expression vector containing a nucleic acid encoding a cell surface molecule directed to recognize a cancer antigen; as well as (b-2) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую IL-7, и нуклеиновую кислоту, кодирующую CCL19;(b-2) an expression vector comprising a nucleic acid encoding IL-7 and a nucleic acid encoding CCL19; (c) следующие два экспрессирующих вектора (с-1) и (с-2):(c) the following two expression vectors (s-1) and (s-2): (с-1) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую молекулу клеточной поверхности, направлено распознающую раковый антиген, и нуклеиновую кислоту, кодирующую IL-7; а также(c-1) an expression vector comprising a nucleic acid encoding a cell surface molecule directed to a cancer antigen recognition and a nucleic acid encoding IL-7; as well as (с-2) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую CCL19;(c-2) an expression vector comprising a nucleic acid encoding CCL19; (d) следующие два экспрессирующих вектора (d-1) и (d-2):(d) the following two expression vectors (d-1) and (d-2): (d-1) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую IL-7; а также(d-1) an expression vector comprising a nucleic acid encoding IL-7; as well as (d-2) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую молекулу клеточной поверхности, направлено распознающую раковый антиген, и нуклеиновую кислоту, кодирующую CCL19; а также(d-2) an expression vector comprising a nucleic acid encoding a cell surface molecule directed to a cancer antigen recognition and a nucleic acid encoding CCL19; as well as (e) следующие три экспрессирующих вектора (е-1), (е-2) и (е-3):(e) the following three expression vectors (e-1), (e-2) and (e-3): (е-1) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую молекулу клеточной поверхности, направлено распознающую раковый антиген;(e-1) an expression vector containing a nucleic acid encoding a cell surface molecule directed to recognize a cancer antigen; (е-2) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую IL-7; а также(e-2) an expression vector comprising a nucleic acid encoding IL-7; as well as (е-3) экспрессирующий вектор, содержащий нуклеиновую кислоту, кодирующую CCL19.(e-3) an expression vector comprising a nucleic acid encoding CCL19. 6. Экспрессирующий вектор по п. 5, в котором молекула клеточной поверхности, направлено распознающая раковый антиген, представляет собой Т-клеточный рецептор, направлено распознающий раковый антиген.6. The expression vector according to claim 5, wherein the cell surface molecule directed to recognize the cancer antigen is a T cell receptor directed to the recognition of cancer antigen. 7. Экспрессирующий вектор по п. 5 или 6, в котором7. The expression vector according to claim 5 or 6, in which нуклеиновая кислота, кодирующая молекулу клеточной поверхности, направлено распознающую раковый антиген, нуклеиновая кислота, кодирующая IL-7, и нуклеиновая кислота, кодирующая CCL19, в экспрессирующем векторе (а); илиa nucleic acid encoding a cell surface molecule directed to a cancer antigen recognition, a nucleic acid encoding IL-7, and a nucleic acid encoding CCL19 in an expression vector (a); or нуклеиновая кислота, кодирующая IL-7 и нуклеиновая кислота, кодирующая CCL19 в экспрессирующем векторе (b-2); илиnucleic acid encoding IL-7 and nucleic acid encoding CCL19 in an expression vector (b-2); or нуклеиновая кислота, кодирующая молекулу клеточной поверхности, направлено распознающую раковый антиген, и нуклеиновая кислота, кодирующая IL-7 в экспрессирующем векторе (с-1), илиa nucleic acid encoding a cell surface molecule is directed to recognize a cancer antigen, and a nucleic acid encoding IL-7 in an expression vector (s-1), or нуклеиновая кислота, кодирующая молекулу клеточной поверхности, направлено распознающую раковый антиген, и нуклеиновая кислота, кодирующая CCL19 в экспрессирующем векторе (d-2)a nucleic acid encoding a cell surface molecule is directed to recognize a cancer antigen, and a nucleic acid encoding CCL19 in an expression vector (d-2) связаны посредством последовательности, кодирующей саморасщепляющийся пептид.linked by a sequence encoding a self-cleaving peptide. 8. Экспрессирующий вектор по пп. 5-7, в которых экспрессирующий вектор содержит нуклеиновую кислоту, кодирующую «суицидальный» ген.8. Expression vector according to paragraphs. 5-7, in which the expression vector contains a nucleic acid encoding a "suicidal" gene. 9. Противоопухолевое средство, содержащее иммунокомпетентную клетку по пп. 1-4 и фармацевтически приемлемую добавку.9. An antitumor agent containing an immunocompetent cell according to paragraphs. 1-4 and a pharmaceutically acceptable additive.
RU2018135652A 2016-03-17 2017-03-15 Immunocompetent cell and expression vector expressing regulatory factors of immune function RU2770812C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-053913 2016-03-17
JP2016053913 2016-03-17
PCT/JP2017/010437 WO2017159736A1 (en) 2016-03-17 2017-03-15 Immunocompetent cell and expression vector expressing regulatory factors of immune function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022109705A Division RU2022109705A (en) 2016-03-17 2017-03-15 IMMUNOCOMPETE CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION

Publications (3)

Publication Number Publication Date
RU2018135652A true RU2018135652A (en) 2020-04-17
RU2018135652A3 RU2018135652A3 (en) 2020-08-24
RU2770812C2 RU2770812C2 (en) 2022-04-22

Family

ID=59851517

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018135652A RU2770812C2 (en) 2016-03-17 2017-03-15 Immunocompetent cell and expression vector expressing regulatory factors of immune function

Country Status (18)

Country Link
US (4) US11337997B2 (en)
EP (1) EP3431597B1 (en)
JP (5) JP6561372B2 (en)
KR (5) KR20230017358A (en)
CN (2) CN109153989B (en)
AU (1) AU2017235116B2 (en)
BR (1) BR112018068314A2 (en)
CA (1) CA3017442A1 (en)
IL (1) IL261707B2 (en)
MX (2) MX2018010974A (en)
MY (1) MY190565A (en)
NZ (1) NZ746168A (en)
PH (1) PH12018550156A1 (en)
RU (1) RU2770812C2 (en)
SG (1) SG11201807857PA (en)
TW (3) TW202313966A (en)
WO (1) WO2017159736A1 (en)
ZA (1) ZA201805913B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201807857PA (en) * 2016-03-17 2018-10-30 Univ Yamaguchi Immunocompetent cell and expression vector expressing regulatory factors of immune function
WO2018119518A1 (en) 2017-01-01 2018-07-05 Lee Chi Yu Gregory Rp215 chimeric antigen receptor construct and methods of making and using same
AU2018242408B2 (en) * 2017-03-27 2022-08-04 Noile-Immune Biotech, Inc. Chimeric antigen receptor
WO2019073973A1 (en) 2017-10-10 2019-04-18 国立大学法人山口大学 Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells
CN111511911B (en) * 2017-12-24 2023-11-03 诺伊尔免疫生物科技株式会社 Immunocompetent cells expressing cell surface molecules that specifically recognize human mesothelin, IL-7, and CCL19
KR20210018838A (en) 2018-05-15 2021-02-18 카르스젠 테라퓨틱스 컴퍼니, 리미티드 Genetically engineered cells and applications
US20230071098A1 (en) * 2018-07-17 2023-03-09 Noile-Immune Biotech, Inc. Anti-gpc3 single-chain antibody-containing car
MX2022004962A (en) * 2019-10-28 2022-08-16 Noile Immune Biotech Inc Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product.
CN111849910B (en) * 2020-05-27 2021-06-15 南京北恒生物科技有限公司 Engineered immune cells and their uses
CN112063588A (en) * 2020-08-13 2020-12-11 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
CN116391030A (en) * 2020-10-28 2023-07-04 Tsd 生命科学有限公司 Transformed immune cells that induce chemotaxis of heterogeneous immune cells
WO2023286840A1 (en) 2021-07-16 2023-01-19 ノイルイミューン・バイオテック株式会社 Anti-egfrviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptide
TW202307009A (en) 2021-07-16 2023-02-16 日商諾伊爾免疫生物科技股份有限公司 Chimeric antigen receptor, cell expressing the receptor,pharmaceutical composition containing the cell, method of producing the cell, and polynucleotide or vector containing base sequence encoding the chimeric antigen receptor
AU2022318416A1 (en) * 2021-07-29 2024-01-25 Takeda Pharmaceutical Company Limited Engineered immune cell that specifically targets mesothelin and uses thereof
CN115704010A (en) * 2021-08-11 2023-02-17 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
CN115873801A (en) * 2021-09-29 2023-03-31 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
CN115651913A (en) * 2022-09-28 2023-01-31 福建基源生物医药有限公司 Cells with antitumor activity and methods for inhibiting tumor growth
WO2024071411A1 (en) 2022-09-30 2024-04-04 国立大学法人京都大学 IMMUNE CELL INDUCED FROM iPS CELL
CN115975946A (en) * 2022-12-01 2023-04-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Immune cells expressing chemokines CXCL10, CXCL13, CCL19, preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688433A4 (en) * 2003-10-09 2008-06-04 Kyowa Hakko Kogyo Kk ANTIBODY COMPOSITION SPECIFICALLY INDUCING GANGLIOSIDE GM2
CA2739902A1 (en) * 2008-10-08 2010-04-15 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
US20130195800A1 (en) 2010-03-23 2013-08-01 Intrexon Corporation Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9233125B2 (en) 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
CN102539745B (en) * 2010-12-31 2013-03-06 中国人民解放军第三〇九医院 Early diagnosis and early warning kit for renal transplant rejection
EP3326467B1 (en) * 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
JP6117515B2 (en) 2011-11-01 2017-04-19 国立大学法人名古屋大学 Pharmaceutical composition for meningioma treatment
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013235600B2 (en) * 2012-03-21 2017-12-07 Dana-Farber Cancer Institute, Inc. Isolation and use of human lymphoid organ-derived suppressive stromal cells
MY167722A (en) * 2014-10-09 2018-09-21 Univ Yamaguchi Car expression vector and car-expressing t cells
SG11201807857PA (en) * 2016-03-17 2018-10-30 Univ Yamaguchi Immunocompetent cell and expression vector expressing regulatory factors of immune function
CN112226462A (en) * 2020-10-12 2021-01-15 广东昭泰体内生物医药科技有限公司 Expression vector for co-expressing secretory IL-7 and selective CCL19 and application thereof

Also Published As

Publication number Publication date
KR20240116832A (en) 2024-07-30
IL261707A (en) 2018-10-31
JP2024096903A (en) 2024-07-17
BR112018068314A2 (en) 2019-01-15
TW202313966A (en) 2023-04-01
KR102186180B1 (en) 2020-12-03
CN109153989B (en) 2022-10-28
JP7479082B2 (en) 2024-05-08
KR20180127403A (en) 2018-11-28
CN115896120A (en) 2023-04-04
JPWO2017159736A1 (en) 2019-01-31
CN109153989A (en) 2019-01-04
EP3431597A1 (en) 2019-01-23
JP2021121198A (en) 2021-08-26
KR102495308B1 (en) 2023-02-06
TW201734205A (en) 2017-10-01
MY190565A (en) 2022-04-27
US11931381B2 (en) 2024-03-19
JP6884423B2 (en) 2021-06-09
ZA201805913B (en) 2019-07-31
AU2017235116B2 (en) 2019-11-07
US20220273723A1 (en) 2022-09-01
MX2018010974A (en) 2019-03-28
RU2770812C2 (en) 2022-04-22
SG11201807857PA (en) 2018-10-30
NZ746168A (en) 2022-04-29
IL261707B2 (en) 2024-10-01
MX2023005317A (en) 2023-05-19
JP6561372B2 (en) 2019-08-21
RU2018135652A3 (en) 2020-08-24
AU2017235116A1 (en) 2018-10-11
KR20200137030A (en) 2020-12-08
CA3017442A1 (en) 2017-09-21
US20240226157A1 (en) 2024-07-11
US20240307451A1 (en) 2024-09-19
JP2023029553A (en) 2023-03-03
TWI789348B (en) 2023-01-11
PH12018550156A1 (en) 2019-03-04
JP2019154455A (en) 2019-09-19
EP3431597B1 (en) 2026-01-21
IL261707B1 (en) 2024-06-01
EP3431597A4 (en) 2019-11-13
US11337997B2 (en) 2022-05-24
CN115896120B (en) 2025-08-05
WO2017159736A1 (en) 2017-09-21
US20190099446A1 (en) 2019-04-04
TW202500743A (en) 2025-01-01
KR20230017358A (en) 2023-02-03
KR20240115908A (en) 2024-07-26

Similar Documents

Publication Publication Date Title
RU2018135652A (en) IMMUNOCOMPETENT CELL AND EXPRESSING VECTOR, EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION
JP2023029553A5 (en)
EA201790624A1 (en) AIMING OF CYTOTOXIC CELLS WITH CHEMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
CL2020001985A1 (en) Peptides and peptide combinations for use in immunotherapy against chronic lymphocytic leukemia (LLC) and other cancers. (divisional request 201801532)
CR20200014A (en) POLYPEPTIDE MOLECULE WITH ENHANCED DUAL SPECIFICITY
EA202191107A1 (en) NY-ESO-1 T-CELL RECEPTORS AND METHODS OF THEIR APPLICATION
CO2018011972A2 (en) T cell receptors
CR20160531A (en) NEW IMMUNOTHERAPY AGAINST VARIOUS TUMORS OF BLOOD, LIKE ACUTE MYELOGEN LEUKEMIA (LMA)
MX384006B (en) TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS AND METHODS OF USING THEM.
CY1124518T1 (en) TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS
MX2022001222A (en) ANTIBODIES TO IMMUNOGLOBULIN PROTEIN OF T LYMPHOCYTES AND MUCIN DOMAIN 3 (TIM-3) AND METHODS FOR USE THEM.
CL2018002792A1 (en) Flt3 chimeric receptors and methods of use thereof.
MX383216B (en) ANTIBODIES DIRECTED AGAINST T-CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3).
MX395153B (en) T CELL RECEPTORS.
BR112017013981A2 (en) anti-cll1-specific chimeric single-chain antigen receptors (sccars) for cancer immunotherapy
MX2017001403A (en) Bispecific single chain antibody construct with enhanced tissue distribution.
BR112021025548A2 (en) Mage-a4 t-cell receptors and methods of using them
PE20190477A1 (en) NEW T-LYMPHOCYTE AND IMMUNOTHERAPY RECEPTORS BASED ON THE USE OF THE SAME
CR20200409A (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
CL2019003423A1 (en) New peptides (seq id no 378), combinations of peptides and carriers for use in the immunotherapeutic treatment of various types of cancer. (divisional request 201800545)
EA201691631A1 (en) CANCER IMMUNOTHERAPY WITH THE USE OF COMBINATION OF LOCAL AND SYSTEMIC IMMUNE STIMULATION
EA201791381A1 (en) UNIVERSAL T-KILLER CELL
AR116141A1 (en) CATALYST CONTAINING NOR FOR OLIGOMERIZATION OF OLEFINS
TR201910573T4 (en) Stabilized proteins to immunize against Staphylococcus aureus.
CY1124141T1 (en) ANTI-CD28 HUMANIZED ANTIBODIES FORMULATED FOR HUMAN ADMINISTRATION